218 related articles for article (PubMed ID: 16857825)
1. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
3. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
4. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
Ray M; Salgia R; Vokes EE
Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
[TBL] [Abstract][Full Text] [Related]
5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
6. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
7. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
Cascone T; Gridelli C; Ciardiello F
Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
Agelaki S; Georgoulias V
Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes.
Wheatley-Price P; Shepherd FA
Curr Opin Oncol; 2008 Mar; 20(2):162-75. PubMed ID: 18300766
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
12. HKI-272 in non small cell lung cancer.
Wong KK
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4593-6. PubMed ID: 17671147
[TBL] [Abstract][Full Text] [Related]
13. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?
Dziadziuszko R; Hirsch FR; Varella-Garcia M; Bunn PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4409s-4415s. PubMed ID: 16857819
[TBL] [Abstract][Full Text] [Related]
14. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
15. EGFR-directed therapies to treat non-small-cell lung cancer.
Ho C; Laskin J
Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
[TBL] [Abstract][Full Text] [Related]
16. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
18. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
19. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
20. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]